Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Pinetree Capital-PNP-CDNX -- Ignore unavailable to you. Want to Upgrade?

To: Jim O'Connell who wrote (148)	2/16/2000 5:26:00 PM
From: the Chief	Read Replies (2) \| Respond to of 233

This is another reason why PNP is moving....VGIN up $11 on the day today NEW DHHS GUIDELINES CONFIRM ROLE OF HIV GENOTYPING GUIDELINES REFERENCE GART AND VIRADAPT STUDIES IN SUPPORTING CLINICAL UTILITY OF Genotypic Drug Resistance Testing NEW DHHS GUIDELINES CONFIRM ROLE OF HIV GENOTYPING GUIDELINES REFERENCE GART AND VIRADAPT STUDIES IN SUPPORTING CLINICAL UTILITY OF Genotypic Drug Resistance Testing TORONTO, Feb 7, 2000 /PRNewswire via COMTEX/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN) announced that the recently released U.S. Department of Health and Human Services' (DHHS) "Guidelines for the Use of Antiretroviral Agents in HIV- Infected Adults and Adolescents," further validates the potential utility of genotypic testing in the clinical management of HIV drug therapy. The guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection convened by DHHS and the Henry J. Kaiser Family Foundation. "The guidelines support the use of genotyping resistance tests as a rapid means to assist in the selection of the appropriate antiviral drug regimen in the treatment of HIV infected patients, especially in cases of virologic failure," said Richard Daly, CEO of Visible Genetics. "We are particularly encouraged that the prospective studies, VIRADAPT and GART, were cited in the guidelines as indicating that the short-term virologic response to therapy was significantly greater when results of resistance testing were available." The two prospective studies, reported last year, showed a statistically significant decrease in HIV viral load by using HIV genotyping to assist in HIV drug selection. The VIRADAPT study, sponsored in Europe by VGI, and the GART study, an independent study conducted in the US by the Community Program for Clinical Research on AIDS (CPCRA), both showed a 0.5 log greater decrease in viral load for patients in the genotyping arm of the study, versus those in the control arm. The VIRADAPT study was published in the June 26, 1999 issue of The Lancet, a peer-reviewed medical journal. Further support for genotyping technology came last September when the US Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) recommended the reclassification of all HIV genotyping drug resistance assays from Class III to Class II with special controls. Approval by the FDA of an HIV genotyping test will also address a key concern cited in the DHHS guidelines that existing unapproved assays "lack uniform quality assurance." VGI expects to file its FDA submission in the first half of 2000. Visible Genetics Inc. is a leader in the emerging field of pharmacogenomics, which uses genetic information in the identification and analysis of genes to improve patient care and reduce healthcare costs. VGI manufactures and markets high performance automated DNA sequencing systems and complete kits for the analysis of genes linked to disease. The Company's OpenGene(TM) system employs patented CLIP(TM) technology -- a single-step, bi- directional sequencing method that significantly reduces the time and cost involved in identifying clinically relevant genetic information. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act 1995. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause the Company's results to differ materially from expectations. These include risks relating to the ability to obtain regulatory approval, market acceptance of genotyping and the Company's products, and other risks as detailed from time to time in the Company's SEC filings and most recent Annual Report on Form 20-F. These forward-looking statements speak only as of the date hereof. VGI disclaims any intent or obligation to update these forward-looking statements. SOURCE Visible Genetics, Inc. (C) 2000 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Paula Evangelista, Director of Public Relations, 215-491-0162, or paula@visgen.com, or Bruno Maruzzo, Director of Investor Relations, 416-813-3271, or bruno@visgen.com, both of Visible Genetics Inc. WEB PAGE: visgen.com GEOGRAPHY: Ontario INDUSTRY CODE: BIO MTC